The Gambling Game of Shorting Bitcoin at its Zenith: Unpacking the Risks!
Unusual Discount on Binance Bitcoin Futures Indicates Institutional Hedging and Potential Short Squeeze Opportunity
Key Points
- Binance’s BTC Perpetual Futures are reportedly trading below spot, indicating hidden institutional short pressure.
- A return to a positive Futures Premium could potentially trigger a significant short squeeze and rapid price breakout.
Binance’s perpetual futures are trading at a discount despite Bitcoin’s [BTC] near-record highs, suggesting an unseen pressure in the market.
Perpetual Futures and Market Premium
Perpetual Futures, a kind of derivative contract, usually mimic spot price movement without an expiry. In bullish markets, they often trade at a premium to spot, showcasing traders’ readiness to pay more for leveraged exposure.
This premium is sustained through Funding Rates, which are regular payments between long and short positions to keep prices in line. Normally, a positive funding and a Futures premium are indicators of a confident market. However, when BTC Futures begin trading at a discount, particularly during all-time highs, it implies that something is amiss.
Interpreting the Gap
Since the beginning of June, Binance’s BTC Perpetual Futures have consistently traded $40-$50 below spot, even as Bitcoin hovers near its all-time high. This deviation is one of the most prolonged discounts in recent years, and it signifies a build-up of underlying market tension.
This divergence might be due to sophisticated institutional strategies. ETFs that accumulate spot Bitcoin may be hedged by shorting futures, which subsequently suppresses perpetual prices. Meanwhile, arbitrageurs are likely profiting by selling futures and buying spot.
However, derivatives traders remain cautious, holding back on leverage despite the bullish price action. This sets the stage for a possible short squeeze. If the perpetual discount flips back to a premium, it could trigger forced liquidations and spark a swift breakout. Long-term whales are holding firm, which makes short-selling a potentially risky gamble.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
